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All human cells are coated by a surface layer of proteoglycans, glycosaminoglycans
(GAGs) and plasma proteins, called the glycocalyx. The glycocalyx transmits shear
stress to the cytoskeleton of endothelial cells, maintains a selective permeability
barrier, and modulates adhesion of blood leukocytes and platelets. Major components
of the glycocalyx, including syndecans, heparan sulfate, and hyaluronan, are shed
from the endothelial surface layer during conditions including ischaemia and hypoxia,
sepsis, atherosclerosis, diabetes, renal disease, and some viral infections. Studying
mechanisms of glycocalyx damage in vivo can be challenging due to the complexity of
immuno-inflammatory responses which are inextricably involved. Previously, both static
as well as perfused in vitro models have studied the glycocalyx, and have reported
either imaging data, assessment of barrier function, or interactions of blood components
with the endothelial monolayer. To date, no model has simultaneously incorporated
all these features at once, however such a model would arguably enhance the study
of vasculopathic processes. This review compiles a series of current in vitro models
described in the literature that have targeted the glycocalyx layer, their limitations, and
potential opportunities for further developments in this field.
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INTRODUCTION
All cells in humans are coated by a surface layer of glycans called the glycocalyx (1, 2). This
coating is a matrix consisting of various proteoglycans, glycosaminoglycans (GAGs), and plasma
proteins, and it provides endothelial cellular mechano-sensation and transduction (3). Its principal
GAGs include heparan sulfate (HS) and hyaluronic acid (HA), and core proteins primarily include
syndecans and glypicans (1). The composition of the glycocalyx is in a state of constant flux, as
it continuously replenishes components that are removed by flowing plasma (4). The glycocalyx
offers a scaffold to which plasma proteins and GAGs may bind (4, 5), and remains an inactive
structure until plasma constituents are bound, at which point it becomes the physiologically active
endothelial surface layer (6).
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In health, the glycocalyx performs a number of physiological
functions, including the exertion of profound influence of
shear stress on the vascular wall, maintenance of a selective
permeability barrier and a low hydraulic conductivity, and
modulation of adhesion of blood leukocytes and platelets
(7). These responses are vital for the regulation of blood
pressure, maintenance of tissue perfusion, and control of
leukocyte recruitment during innate immune responses and
inflammation (8). In particular, its constituent GAGs play
a key role in cell-cell signaling and tissue injury. Innate
immune cells, such as fibroblasts, mast cells, dendritic cells,
monocytes and neutrophils recognize pathogenic invasion using
pattern recognition receptors. When activated, these receptors
drive signaling cascades which ultimately recruit leucocytes
to the site of tissue injury (9). Furthermore, cytokines such
as tumor necrosis factor (TNF) and interleukin 1 (IL1)
promote leukocyte extravasation by increasing the levels of
leukocyte adhesion molecules on endothelial cells (9). In a
murine model by Wang et al. reducing sulphation by 60%
with an endothelium-specific knockout of N-acetyl glucosamine
N-deacetylase-N-sulfotransferase-1, which is required for the
addition of sulfate to heparan sulfate chains, decreased neutrophil
infiltration (10). This emphasizes the extent to which glycocalyx
integrity modulates feedback between innate immune responses
and inflammation.
The glycocalyx is also critically involved in angiogenesis. A
study by Park-Windol et al. reported that in vitro knockout of
endomucin-1, an integral membrane glycocalyx glycoprotein,
reduced migration, inhibited cell growth without compromising
cell survival, and suppressed tube morphogenesis of endothelial
cells, whereas over-expression of endomucin-1 led to increased
migration, proliferation and tube formation (11).
During homeostatic conditions, the glycocalyx lies in dynamic
equilibrium between shedding of its components following
the shear stress of blood flow, and de novo synthesis of its
components, such as hyaluronic acid, by endothelial cells (12).
The glycocalyx, being a dynamic structure, is also readily
susceptible to injury. Destruction of the endothelial glycocalyx,
which ranges from 200 to 2,000 nm in thickness, decreases
vascular barrier function and leads to protein extravasation and
tissue oedema, loss of substrate supply to tissues, and an increase
in platelet and leucocyte adhesion (13). Major components
of the glycocalyx, including syndecans, heparan sulfate, and
hyaluronan, are shed from the endothelial surface layer under
various acute and chronic clinical conditions, with the best
characterized examples including ischaemia and hypoxia, sepsis,
atherosclerosis, diabetes, renal disease, and haemorrhagic viral
infections (7). Critically, heparan sulfate and syndecan-1 are
released into the circulation during periods of ischaemia-
reperfusion injury, and these levels reduce accordingly during
therapeutic intervention (14). These may therefore be used as
surrogate biomarkers of endothelial injury (14). Furthermore,
syndecans have been shown to act as soluble messengers.
Jannaway et al. demonstrated that thrombin can cleave syndecan
3/4 ectodomain into fragments which interact with endothelial
cells, causing paracellular hyperpermeability (15). Through
contact independent signaling, this vascular leakage may be
amplified by perivascular cells, such as in the case of Dengue viral
protein NS1 (16).
There has been a significant increase in academic interest
in the role of the glycocalyx in cardiovascular pathophysiology.
Previously, both static as well as perfused in vitro models
have reported imaging data of glycocalyx components under
flow, assessment of barrier function, or the interplay between
blood components (e.g., leucocytes) and the glycocalyx. No
model to date has combined all of these parameters, however
this would be highly advantageous in the study of a vast
array of pathophysiological states (e.g., infective vasculopathies,
ischaemia-reperfusion injury, shock, sepsis, responses to foreign
antigens). This paper aims to review current in vitro models
which study glycocalyx pathophysiology, with an aim to identify
areas of potential further development in this field.
STUDYING THE ENDOTHELIAL
GLYCOCALYX: MODELS AND IMAGING
TECHNIQUES
Given the greatly increased level of interest in the endothelial
glycocalyx in recent years, a wide range of in vitromodels to study
the glycocalyx layer have been developed, integrating a variety
of imaging modalities. These models have been used to study
numerous pathophysiological states, including hyperglycaemia,
endotheliopathy of shock, and ischaemic preconditioning (17–
19). A summary of selected in vitro models in the literature is
given in Table 1.
With reported thicknesses of the glycocalyx being in the order
of nanometres, imaging modalities form a critical component
of any model making an assessment of the glycocalyx in
vivo, as well as the glycocalyx layer in vitro, and this field
has evolved considerably. The first imaging of the endothelial
glycocalyx by electron microscopy (EM) used the cationic dye
ruthenium red (31), with subsequent studies using gold colloids
and immunoperoxidase labeling (32). A major disadvantage of
these methods was the degradation of the glycocalyx, which
occurred with dehydration associated with fixative agents. Many
of the methods incorporating EM yielded endothelial glycocalyx
thicknesses < 100 nm in size (3).
Newer imaging methods to visualize the glycocalyx have since
evolved. These include laser scanning confocal microscopy and
multi-photon microscopy, with fluorescently labeled antibodies
to heparan sulfate or hyaluronic acid binding protein, or
wheat germ agglutinin (which binds to sialic acid) to bind to
components of the endothelial glycocalyx. In comparison to
EM, application of these methods has demonstrated endothelial
glycocalyx thicknesses in large blood vessels of 4,300–4,500 nm
in the mouse common carotid artery, 2,200 nm in the mouse
internal carotid artery, and 2,500 nm in the external carotid artery
(33–35). Novel cryogenic protocols combined with electron
microscopy have yielded promising results, with one study
by Ebong et al. demonstrating that a rapid freezing/freeze
substitution method combined with transmission electron
microscopy revealed substantial glycocalyx layers on cultured
endothelial cells (26). However, more recently, chemical and

























TABLE 1 | Summary of in vitro models that directly study glycocalyx pathophysiology.




Diebel et al. (18) In vitro; Transwell
plates
HUVECs Static Cell media Cells exposed to hydrogen peroxide
and/or adrenaline to stimulate
post-trauma/haemorrhagic shock.
The effect of early administration of
tranexamic acid (TXA) on mitigating















Antifibrinolytic and other protective
effects of TXA administration on
endothelial injury were
time-dependent, supporting the
concept that clinical efficacy of
tranexamic acid requires “early
administration.”
Martin et al. (20) In vitro; Transwell
plates
HUVECs Static Cell media HUVECs were treated with varying
concentrations of noraderenaline and












Noradrenaline induced a fibrinolytic
state with elevated tPA levels
compared to adrenaline. Both
degraded the glycocalyx, however
adrenaline appeared to produce more
severe endothelial instability as










Static Cell media Confluent human pulmonary
microvascular endothelial cell
(HPMECs) monolayers grown on
gelatin-coated coverslips were
exposed to different concentrations of
Dengue virus (DENV) non-structural
protein 1 (NS1)
Immunofluorescence
staining: WGA lectin conjugated
to Alexa 647 to stain N-acetyl
neuraminic acid (Sia); anti-human
heparanase 1, anti-human
cathepsin L; anti-heparan sulfate










electrical resistance, using an
epithelial volt ohm meter with
“chopstick” electrodes.
DENV NS1 disrupted the endothelial
glycocalyx on human pulmonary
microvascular endothelial cells,
inducing degradation of sialic acid
and shedding of heparan sulfate
proteoglycans. NS1 also activated
cathepsin L, a lysosomal cysteine
proteinase, in endothelial cells, which
















































































TABLE 1 | Continued














Static Cell media NS1 proteins added to confluent
monolayers of human endothelial
cells, and amount of NS1 bound to
the surface of the endothelial cell
monolayers was determined by
immunofluorescence microscopy.
Alterations in permeability assessed
using TEER and solute flux assays
Staining: For sialic acid, wheat
germ agglutinin (WGA)
conjugated to Alexa Fluor 647
(5µg/ml); for heparan sulfate,
anti-heparan sulfate antibody
(1:50 in 1X PBS, primary) and
anti-mouse IgM Alexa Fluor 488





Epithelial Volt Ohm Meter, and a
solute flux assay using measured
fluorescence of include
fluorescein isothiocyanate (FITC).
NS1 proteins from dengue, Zika,
West Nile, Japanese encephalitis, and
yellow fever viruses selectively alter
the permeability of monolayers of
endothelial cell lines derived from
distinct human tissues. Flavivirus NS1
proteins modulate endothelial
permeability in a tissue-specific




Wang et al. (23) In vitro/in vivo;
Transwell plates
HUVECs Static Cell media Investigation of effect of platelet
microparticles (PMPs) in diabetes on
aortic vascular endothelial injury.
In vitro: cells treated with
platelet microparticles
Imaging: Wheat germ agglutinin





Increased PMPs levels contributed to
aortic vascular endothelial injuries in
diabetes through activating the
mTORC1 pathway












Investigation of the effect of salt and
aldosterone exposure on pathologic
remodeling of the glomerular
glycocalyx.
In vitro: cells exposed to 0.1 nM
aldosterone and 145 mMol NaCl.
In vivo: murine model of
administration of 0.6 µg/g/d of
aldosterone (subcutaneous









Reduction in cell surface glycocalyx
components (heparan sulfate and
syndecan-4) and disrupted shear
sensing was observed consistent with
damage of the glycocalyx, when cells
were exposed to 0.1 nM aldosterone
and 145 mMol NaCl.
Targeting matrix metalloproteinases 2
and 9 with a specific gelatinase
inhibitor preserved the glycocalyx









Static Cell media In vivo and in vitro examination of the
relative contributions of inflammatory
mediators and endothelial
cell-intrinsic pathways in endothelial
dysfunction induced by Dengue virus
(DENV) non-structural protein 1
(NS1).
In vitro: human dermal endothelial
cells exposed to DENV NS1.
In vivo: Murine model of vascular leak









on HMEC-1 monolayers to
assess glycocalyx components
(sialic acid, chondroitin sulfate,
















































































TABLE 1 | Continued




microvascular endothelial cell line
HMEC-1 stimulated with DENV2
NS1 and supernatant collected
Permeability in vivo:
retro-orbital (RO) injection of IV
injection of dextran molecules
labeled with a fluorophore (Alexa
Fluor 680), which can be
quantified via
fluorescent scanning
In vivo, DENV NS1 but not West Nile
virus NS1 triggered localized vascular
leak in the dorsal dermis of wild-type
C57BL/6 mice. In vitro, human
dermal endothelial cells exposed to
DENV NS1 did not produce
inflammatory cytokines (TNF-α, IL-6,
IL-8). Blocking these cytokines did
not affect DENV NS1-induced
endothelial hyperpermeability.
DENV NS1-induced endothelial
cell-intrinsic vascular leak was
independent of inflammatory
cytokines, but dependent on
endothelial glycocalyx components
In vitro (Glass)
Ebong et al. (26) In vitro; glass
Corning slides
Bovine aortic (BAEC)
and rat fat pad
endothelial cells




Imaging (RF/FS TEM): Cells
were quick frozen in a Life Cell
CF 100 slam freezer by
impacting the cell monolayer
against a polished sapphire
surface cooled to liquid nitrogen
temperature. Freeze substitution
performed in acetone containing
1% osmium tetroxide.
Imaging (Immunoconfocal):
Heparan sulfate (HS) and
hyaluronic acid (HA) were labeled
with anti-HS and HA binding
protein, respectively
RF/FS-TEM revealed impressively
thick bovine aortic endothelial cell
glycocalyx of ∼11µm and rat fat pad












Cell media Cells seeded within 3D straight tube
models and subjected to 24 h of 10
dyn/cm2 laminar shear stress,
investigating the role of glycocalyx in
leukocyte adhesion under flow
Staining: Primary antibodies
(Heparan sulfate, 1:100, Millipore
MAB2040 and ICAM-1, 1:200,
Santa Cruz sc-8349
monoclonal); Secondary




staining with laser scanning
confocal microscopy
With enzymatic degradation of the
glycocalyx, endothelial cells
developed a proinflammatory
phenotype when exposed to uniform
steady shear stress leading to an















































































TABLE 1 | Continued
References Model type EC cell type Flow condition Model fluid Research question/model details Method of assessment of
endothelial surface layer
Relevant outcomes










Cell media Murine cremasteric muscle and
vasculature exteriorized under
anesthesia
Imaging in vitro: micro-particle
image velocimetry
Microviscometric analysis of µ-PIV
data determines the hydrodynamically
relevant glycocalyx thickness, which
may be more physiologically relevant
and meaningful than the molecular or
structural dimension of the glycocalyx
measured using direct visualization
methods





BAECs, HUVECs Steady state
perfusion (15
dyn/cm2)
Cell media Role of the glycocalyx in both
endothelial cell short-term and
long-term mechano-transduction
responses by using heparinase III to
cleave heparan sulfate GAGs on the
cell surface
Staining: CellTrace Red-Orange
AM (Invitrogen) to detect
cellnuclei; VE-cadherin antibody
(BD Transduction Laboratories)
to detect cell-cell junctions.
Imaging: Cooled
charge-coupled device camera
(Apogee Instruments) on a Nikon
Eclipse TE2000 microscope with
a 63 water-immersion objective
and MaxIm DLsoftware
(Apogee Instruments).
Removing the glycocalyx by using the
specific enzyme heparinase III,
endothelial cells no longer align under
flow after 24 h and they proliferate as
if there were no flow present.
Glycocalyx is necessary for the
endothelial cells to respond to fluid
shear, and the glycocalyx itself is












dyn/cm2 for 24 h)
Cell media Effects of shear stress on the spatial
distribution of the glycocalyx on
endothelial cell membranes
Staining: WGA used to bind to
N-acetyl-D-glucosamine and





Following 24 h recovery under shear
flow, the glycocalyx reappears
predominantly near the edge of
endothelial cells. Static and shear
flow conditions result in notable
changes in the spatial recovery of the
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FIGURE 1 | Areas for potential enhancement for existing in vitro benchtop models studying glycocalyx pathophysiology. Acknowledgment: Biorender.com.
cryogenic fixation have been shown to lead to substantial collapse
of the glycocalyx (36).
Sidestream dark field imaging (SDF) is a non-invasive
technique and has been used to analyse the glycocalyx in
vivo. In a bedside evaluation of the sublingual microvascular
glycocalyx in sepsis, acutely ill patients demonstrated damage
to the glycocalyx compared to healthy control subjects, with
more severe alterations during sepsis (37). One observational
study based in Vietnam demonstrated that in patients with
Dengue, SDF imaging demonstrated disruption to the glycocalyx,
with worse observed glycocalyx injury and higher plasma
concentrations of degradation products being associated with
worse plasma leakage. The authors reported that in patients with
dengue, the perfused boundary region (PBR hf), a surrogate
for glycocalyx degradation, was higher in patients with Grade
2 vs. Grade 0 plasma leakage during the critical phase (PBR hf
1.96 vs. 1.36µm for Grade 2 vs. Grade 0 plasma leakage on
days 4–6, respectively, p < 0.001) (38). SDF, unfortunately, also
has associated drawbacks including that it is prone to impaired
visualization of capillaries, as well as interference of moving
blood components, such as erythrocytes, with the quality of the
image obtained (39).
Importantly, techniques such as confocal microscopy
and SDF are applicable both in vivo and in vitro, whilst
the need to fix samples for scanning electron microscopy
precludes its use in vivo. The pursuit of the optimal imaging
modality for studying the glycocalyx remains a field of
ongoing research.
LIMITATIONS OF EXISTING IN VITRO
MODELS
Whilst a number of studies have successfully demonstrated the
structure, shedding and function of the endothelial glycocalyx
layer across a range of different pathophysiological conditions,
there are inherent limitations remaining with current in vitro
models. Thesemay be approached systematically using categories
of (1) flow conditions, (2) materials employed, (3) assessment
of endothelial barrier function, and (4) usage of blood products
(Figure 1).
Static vs. Dynamic Flow Conditions
A critical component in the investigation of the glycocalyx layer
is the exposure of the cells to dynamic, rather than static, flow
conditions that more closely model physiological conditions. The
use of static endothelial cell models, usually Transwell systems,
readily enables the assessment of endothelial barrier function
and its response to chemical or biological stimuli (20). However,
the morphology of cultured endothelial cells differs considerably
under static compared to perfused conditions, and the thickness
of the glycocalyx has been shown to be limited under static
conditions, which diminishes its physiological relevance (40).
Ueda et al. reported a glycocalyx thickness under static conditions
of ∼22 nm under static conditions (41), in comparison to
Tsvirkun et al. who reported a glycocalyx thickness of ∼600 nm
when cultured under flow conditions (42). This was further
corroborated by Gouverneur et al. who demonstrated that the
Frontiers in Cardiovascular Medicine | www.frontiersin.org 7 April 2021 | Volume 8 | Article 647086
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application of fluid shear stress to cultured HUVECs resulted in
a 3-fold higher level of hyaluronan binding protein compared
to cells under static conditions. This increased incorporation
of hyaluronan may well contribute vasculoprotective properties
against inflammation and atherosclerosis to the glycocalyx (4).
Flow-induced shear stress is not only important for the
development of the glycocalyx, but it also plays a critical role in
maintaining endothelial cell integrity and mechanotransduction
(43), particularly in specific cell signaling processes (44). Thi
et al. showed that a stable glycocalyx layer is required for
the endothelial cell cytoskeleton to respond to shear stress
(45), which activates endothelial nitric oxide synthase (eNOS)
for the production of nitric oxide (46). This enzyme is
critical for modulating the control of vascular tone, leucocyte
immigration, and blood clotting (47). Furthermore, the majority
of studies conducted under flow conditions have integrated
steady-state flow, which provides a constant shear stress on the
endothelial cells. However, physiologic pulsatile flow delivers
fluctuating shear stress. It has been shown previously that
pulsatile flow will vary endothelial cell morphology, enzymatic
activity and gene expression, compared to continuous flow
(48–51); Uzarski et al. demonstrated that variable shear
stress, with temporal changes in pulsatile flow, leads to anti-
inflammatory and anti-thrombotic phenotype expression (50),
in other words, consistent with the homeostatic vascular
endothelium. Furthermore, previous studies have demonstrated
that endothelial phenotypes have changed based on pulse
frequency (52), pulse amplitude (53), and magnitude of shear
stress (54). However, comparative studies of steady-state vs.
pulsatile flow specifically on glycocalyx integrity are few. For
greater translatability, future studies investigating endothelial
and glycocalyx responses to inflammation, coagulation or arterial
wall damage should integrate dynamic flow conditions as a
priority, such as a comparison between steady state laminar fluid
shear stress and pulsatile shear stresses, increased incrementally.
To cite one relevant clinical example, the effect of pulsatile
flow on the microcirculation remains a novel field of significant
academic inquiry. Koning et al. reported outcomes of pulsatile
vs. non-pulsatile flow on microcirculatory perfusion in a
clinical study of patients undergoing coronary artery bypass
graft surgery. Sublingual mucosal microvascular perfusion was
measured using sidestream dark field imaging. The observed
reduction in perfused vessel density during aorta cross-clamping
was only restored in the pulsatile flow group and increased from
15.5± 2.4 to 20.3± 3.7 mm/mm2 upon intensive care admission
(P < 0.01). The median post-operative microvascular flow index
was higher in the pulsatile group [2.6 (2.5–2.9)] than in the
non-pulsatile group [2.1 (1.7–2.5); P= 0.001] (55).
Material Selection and Channel
Dimensions
The materials used in perfused microchannels can have
a large influence on cell morphology and the thickness
of the glycocalyx developed, as the materials will have
different mechanical properties than the native ECM, thereby
changing the stiffness and associated mechanical environment
stimulation of the endothelial cells. Microfluidics is the
technology of fluid manipulation in channels with dimensions
of tens of micrometers (56). Selecting a material for a
microfluidics application can be a sophisticated process.
Flexibility, air permeability, electrical conductivity, non-specific
adsorption, cellular compatibility, solvent compatibility and
optical transparency are all physical characteristics nominated
by Nge et al. as being potentially significant factors affecting
choice of material used in microfluidics applications (57). For
the purposes of microfluidic models to study the endothelium,
biocompatible channel materials that will promote cell adhesion,
growth and differentiation with minimal inflammatory response
are highly favored (58). Silicon and glass were the original
materials used for this purpose. Collagen scaffolds were also
used for early in vitro models that successfully demonstrated
confluent monolayers of endothelial cells. Subsequent studies
built on this concept, extending bioremodelable hydrogels
(type I collagen) to develop 3D microvascular networks, with
user-defined geometries (59). This was followed by a shift
to polymer substrates, and in particular, polydimethylsiloxane
(PDMS) (57), which is able to be manufactured effectively into
small-diameter channels (<1,000µm) if required and provides
sufficient mechanical stiffness to support physiologically relevant
flows at this size.
PDMS has also been shown to support more sophisticated,
fully endothelialized microvascular networks. Tsvirkun et al. first
successfully demonstrated that endothelial cells confined within
microchannels and exposed to a physiologically relevant level of
fluid shear stress exhibit a glycocalyx that lines the entire lumen
of the channels (42). Importantly, PDMS has also demonstrated
pressure-induced deformation under flow, which is important
for simulating vessel compliance (60). One significant drawback
of PDMS is its ability to absorb very small molecules,
which may not be desirable for certain applications (e.g.,
drugs) (61).
Flow channel dimensions, whilst influential on platelet-
surface and platelet-platelet interactions, are not widely reported
in existing models. The shift from platelet-surface interactions
or platelet-platelet interactions occurs as a function of channel
size and aspect ratio (height/width) with values of <0.2 are
being recommended to achieve constant shear stress, and hence
laminar flow (62).
Assessment of Endothelial Barrier
Function
The demonstration of endothelial barrier function is another
important consideration and limitation in current models, in
order to confirm that the presence of observed structural changes
in glycocalyx components are occurring within a functioning
endothelium. A critical characteristic of the endothelium is its
barrier function; therefore, a model that stipulates that it has
replicated the glycocalyx in vitro should also demonstrate that
its barrier function is maintained. Commonly used examples
include direct methods, such as transendothelial electrical
resistance (TEER), or indirect methods using a permeability
Frontiers in Cardiovascular Medicine | www.frontiersin.org 8 April 2021 | Volume 8 | Article 647086
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coefficient from transendothelial filtration of tracer molecules
(e.g., FITC-Dextran).
TEER measurements have become the gold standard for
assessing endothelial monolayer integrity, which typically consist
of a volt-ohm resistance meters fitted with “chopstick” or
chamber electrodes (63). When serial resistance measurements
are taken over time, increasing confluence of the endothelial
monolayer is then reflected by stabilization of resistance.
This may also be corroborated with an observed increase in
confluence, as demonstrated by Ferrell et al. in a microfluidic
bioreactor with integrated TEER capability (64). Advantages of
this method include its relative simplicity and reproducibility
(65); however, it does not demonstrate whether the transition
of a molecule of interest across the endothelial barrier, such as
a protein, occurs or not (66).
In contrast, assessing endothelial barrier function using
permeability studies involve the measured diffusion of a known
concentration of analyte from the apical to basolateral side
of the membrane over a predetermined period of time, also
known as solute flux assays. Commonly used substances to
perform this include fluorescein isothiocyanate (FITC)–dextran,
which is a 3–5 kDa marker used to measure tight junction
permeability (67, 68). A disadvantage of this technique is that
it does not accurately represent the microvascular environment,
due to static conditions on the apical side of the membrane
(63). This is a particularly important drawback to note in
the development of models of vasculopathic processes, as
it may hinder the capacity of such models to study the
impact of pathological stimuli and therapeutic interventions.
It should also be noted that maintained barrier function
alone is not necessarily an absolute indication of a fully
functionally intact glycocalyx. Therefore, in order to address
this concern, other surrogates for glycocalyx integrity must
be considered. For example, an intact glycocalyx is also a
critical regulator of cell membrane expression of gap junction
proteins (69). On the other hand, degraded HS from the
glycocalyx during injury will cause the dislocation of gap
junction alpha-1 protein (Cx43) and malfunction of gap junction
channels (69). Assessing immunohistochemical surrogates for
glycocalyx integrity, such as Cx-containing gap junction activity
by measuring interendothelial spread of gap junction permeable
Lucifer Yellow dye (69), is one potential method to circumvent
this issue.
Use of Blood Products
Finally, the glycocalyx modulates adhesion of leukocytes and
platelets to the endothelium. Incorporating blood products (such
as packed red blood cells, leucocytes, or platelets), allows the
study of the interplay between endothelial damage and immuno-
inflammatory responses, which is not possible if the perfusate is
only cell media. Therefore, an important component in modeling
glycocalyx layer structure and function in vitro is its exposure
to whole blood, blood products, or combinations of the two
(70). Whilst there are inherent difficulties in perfusion culture of
endothelial cells with whole blood, the consideration of blood-
endothelial interactions is nonetheless important. However, the
majority of studies investigating the glycocalyx layer in vitro
have used cell culture media as a perfusate, rather than blood
(Table 1). Urner et al. demonstrated that incubation with blood
products was associated with increased inflammatory mediator
release from endothelial cells (71), whilst McDonald et al.
demonstrated that enzymatic degradation of the endothelial
glycocalyx in cultured endothelial cells under flow resulted
in the development of a proinflammatory phenotype and
an increase in leukocyte adhesion (27). Thus, studies using
microfluidic devices incorporating RBCs or whole blood are
warranted. Anticoagulation is a necessary addition for whole-
blood perfusion studies to minimize thrombus formation;
however, this limits endothelial-blood studies investigating
platelet activation or aggregation (72). Whole blood is also
opaque, which makes real-time imaging of blood-endothelial
interactions difficult (73); however, diluted blood may still allow
for microscopic analysis and therefore retain many advantages of
using blood.
The selection of endothelial cells is a significant, influential
variable. Dong et al. quantitatively examined different sources
of endothelial cells in flow studies. They reported that the
number of ultralong Von Willebrand Factor (VWF) strings
is endothelial source dependent, with fewer ultralarge VWF
strings forming on human coronary artery endothelial cells and
human lung microvascular endothelial cells, both used after 4–5
passages, than on primary HUVECs and human umbilical artery
endothelial cells (74).
Finally, it has been demonstrated by Lanotte et al. that flow
resistance in a microcapillary model could more closely resemble
in vivo scenarios, with a reduction in the velocity of red blood
cells when microcapillaries were coated with a polymer brush
to mimic the glycocalyx (75). This has potential implications
for red blood cell deformation and mechanotransduction of the
endothelial cells and further reinforces the utility of integrating
blood products.
DISCUSSION
There is a significant unmet global need in targeted therapeutics
for endothelial dysfunction. To cite one notorious example,
Dengue is regarded as the most prevalent and rapidly spreading
mosquito-borne viral disease of human beings (76). Whilst
the course of this disease is most frequently self-limiting, a
small proportion will progress to a syndrome characterized by
increased capillary permeability, extravasation of plasma and in
some cases, irreversible shock and death. Currently, there are no
targeted treatment options available, with supportive care being
the cornerstone of management.
Therefore, there is high demand for authentic benchtop
models which can examine vascular pathophysiology, as well as
opportunities for targeted therapeutic strategies, which includes
the glycocalyx. The concept of an “ideal” in vitro model is
attractive, namely because it carries the benefit of tighter control
of experimental variables. In order to advance this field, the
four areas identified by the authors to enhance current in vitro
model design have therefore included the use of dynamic flow
conditions, material selection, assessment of barrier function and
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usage of blood products, as described in section Limitations of
Existing in vitro Models. Their justification, as well as particular
controversies which remain in the study of the glycocalyx in vitro
vs. in vivo, are now discussed as follows.
Firstly, in vitro models carry the distinct advantage that the
glycocalyx layer and its responses to individual variables may
be studied in a highly controlled environment, and therefore
they support mechanistic lines of scientific inquiry. In contrast,
in vivo models offer the distinct advantage of being able to
capture critical biological feedback mechanisms, such as those
between the glycocalyx and acute inflammatory mediators,
which is extremely difficult to replicate in vitro. Furthermore,
whilst the dimensions of the glycocalyx are highly dynamic
and will fluctuate with homeostatic mechanisms, there remains
considerable variation in the literature between dimensions
described from in vivo and in vitro models. Variations in
measured thicknesses of the glycocalyx are even observed from
within the same type of human cell. Chappell et al. reported an
average thickness of 878 +/– 612 nm in six ex vivo umbilical
cords, compared to cultured HUVECs with an average thickness
of 29.4 ± 5.8 nm for the dense zone and of 117.9 ± 39.1 nm
for the outer zone (40). Previous studies have even declared
that the glycocalyx observed in vivo did not exist in vitro at all,
although the conditions under which cells have been cultured
should be carefully noted. One study by Potter and Damiano
described that the glycocalyx observed in microvessels in vivo
was∼520 nm in thickness, but only∼30 nm in thickness in vitro
in human umbilical vein endothelial cells under standard cell
culture conditions (77). This variation of glycocalyx dimensions
in the literature is important, because it effectively forms the
“confidence interval” within which the efficacy of targeted
endothelial protection strategies on glycocalyx preservation may
be determined.
Secondly, another area of controversy is that whilst glycocalyx
components may be demonstrated through imaging, this does
not necessarily correspond to a functioning endothelium. A
critical characteristic of the endothelium is its barrier function;
therefore, a model that stipulates that it has replicated the
glycocalyx in vitro should also demonstrate that its barrier
function is maintained. Whilst several methods, including
TEER and permeability assays, have been well-documented to
demonstrate endothelial barrier function, they are not always
included alongside imaging or quantitative studies of the
glycocalyx. Their usage should arguably now be the minimum
standard in any in vitromodel, and not an optional inclusion.
Thirdly, and as a corollary from the preceding two
points, many models described in the literature have so
far concentrated on providing imaging of the glycocalyx,
demonstrating alterations in its level of permeability, or studying
specific interactions with blood components or proteins of
interest. The majority of these have been demonstrated in a
static environment. Very few, if any, models have been able to
integrate all of these aspects into one model; in other words,
demonstrate the glycocalyx visually, along with assessment of its
barrier function, in a dynamic flow environment. The idealmodel
should be able to perform all of these functions simultaneously.
The addition of blood products to in vitro microfluidics
models represents an attractive frontier to replicate vascular
pathophysiological processes, such as thrombosis, more
faithfully. However, the study of thrombosis specifically applied
to microfluidics devices is notoriously difficult. By definition,
microfluidic models are built around the precise control of flow
rates and volumes in the order of microlitres, or picolitres. As
a result of these minute volumes, it therefore becomes difficult
to obtain Reynolds numbers of sufficient magnitude to obtain
boundary layer separation and reattachment representative of
downstream turbulent flow from a stenotic lesion (78).
The study of coagulation within microfluidics devices is
still in its relative infancy. The performance of conventional
anticoagulants, such as heparin, which is readily used clinically
and in vivo, can vary significantly in the setting of microfluidics.
Two papers are worthy of note in this regard. Firstly, Harris et al.
reported that in a model of human blood being perfused over
porcine endothelial cells, there was a strong reduction in platelet
surface area coverage and thrombus volume upon treatment of
heparinized whole blood with the thrombin inhibitor bivalirudin.
This implied that anticoagulation with heparin was insufficient
to block thrombin generation in this model (79). Secondly,
Ciciliano et al. recalcified citrated blood to allow coagulation
to occur, and reported a reduction in channel occlusion with
hirudin and heparin in this setup (80).
CONCLUSION
The glycocalyx is an essential homeostatic organ and is widely
implicated in medical and surgical pathophysiology. It is also an
elusive, dynamic structure to investigate. Whilst true dimensions
of the glycocalyx may indeed be variable, what remains an
essential priority is that in vitro model designs advance to
the level whereby the endothelium is simultaneously able to
be cultured and studied under perfusion, its surface layer
is able to be consistently imaged, and its barrier function
able to be assessed dynamically. A model of this kind would
be of tremendous value in developing targeted therapeutic
interventions for vasculopathic conditions.
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